Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AMGN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Evolocumab FDA approved Aug 2015 · Repatha |
Cardiovascular Disease | Phase 4 · NCT05284747 | Active not recruiting |
| Erenumab FDA approved May 2018 · Aimovig |
Migraine | Phase 3 · NCT03832998 | Completed |
| Romiplostim FDA approved Aug 2008 · Nplate |
Chemotherapy-induced Thrombocytopenia | Phase 3 · NCT03362177 | Completed |
| Sotorasib (AMG 510) FDA approved May 2021 · Lumakras |
Non-Small Cell Lung Cancer (NSCLC) | Phase 3 · NCT05920356 | Recruiting |
| Tarlatamab FDA approved May 2024 · Imdelltra |
Extensive-Stage Small-Cell Lung Cancer | Phase 3 · NCT06211036 | Active not recruiting |
| Tezepelumab FDA approved Dec 2021 · Tezspire |
Eosinophilic Esophagitis | Phase 3 · NCT05583227 | Active not recruiting |
| Apremilast FDA approved Mar 2014 · Otezla |
Behçet's Disease | Phase 3 · NCT05767047 | Recruiting |
| Carfilzomib FDA approved Jul 2012 · Kyprolis |
Multiple Myeloma | Phase 1/2 · NCT04822337 | Recruiting |
| Blinatumomab FDA approved Dec 2014 · Blincyto |
B Precursor Acute Lymphoblastic Leukemia | Phase 2 · NCT06054113 | Active not recruiting |
| Routine Lipid Management | Cardiovascular Disease | Phase 4 · NCT05284747 | Active not recruiting |
| mFOLFOX6 | Gastric Cancer | Phase 3 · NCT05052801 | Completed |
| Dazodalibep | Sjogren's Syndrome | Phase 3 · NCT06104124 | Completed |
| Maridebart Cafraglutide | Heart Failure With Preserved Ejection Fraction | Phase 3 · NCT07037459 | Recruiting |
| ABP 938 8 mg | Neovascular Age-related Macular Degeneration | Phase 3 · NCT07614776 | Recruiting |
| Olpasiran | Atherosclerotic Cardiovascular Disease | Phase 3 · NCT05581303 | Active not recruiting |
| Bemarituzumab | Gastric Cancer | Phase 3 · NCT05052801 | Completed |
Also used in these trials (approved or third-party drugs, not AMGN's own candidates): Avacopan, Durvalumab, Inebilizumab, Pembrolizumab, Oral Semaglutide, Aflibercept, Mitoxantrone, Ziftomenib, Vorinostat, Pemetrexed Disodium, Methotrexate, Mercaptopurine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AMGN holds $25.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMGN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 48,925,833 | 9.05% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 40,510,484 | 7.49% | 2026-03-31 |
| State Street Corporation | Institution (13F) | 30,955,079 | 5.72% | 2026-09-30 |
| Capital World Investors | Institution (13G, 5%+) | 29,596,119 | 5.47% | 2026-03-31 |
| Invesco Ltd. | Institution (13F) | 16,550,564 | 3.06% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 16,041,602 | 2.97% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 15,053,954 | 2.78% | 2026-09-30 |
| Charles Schwab Investment Management, In | Institution (13F) | 13,984,272 | 2.59% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 13,550,428 | 2.51% | 2026-09-30 |
| Wells Fargo & Company | Institution (13F) | 6,938,636 | 1.28% | 2026-09-30 |
| Robert A Bradway Chairman, CEO and President, Director · +79,176 options |
Insider | 655,220 | 0.12% | 2026-05-07 |
| Esteban Santos EVP, Operations |
Insider | 83,757 | 0.02% | 2026-05-07 |
Share count 540,911,490 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-06 filed 2026-11-09 |
HOLLEY CHARLES M |
Award (A) | 185 | – | 13,262 |
| 2026-11-06 filed 2026-11-09 |
ISHRAK OMAR |
Award (A) | 152 | – | 7,682 |
| 2026-11-06 filed 2026-11-09 |
Gibbs David W |
Award (A) | 278 | – | 278 |
| 2026-11-06 filed 2026-11-09 |
Drake Michael V |
Award (A) | 114 | – | 6,030 |
| 2026-08-13 filed 2026-08-13 |
Khosla Rachna |
Sale (S) | 1,252 | $416.43 | 6,404 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMGN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →